These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3476980)

  • 41. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 42. [Chemical surveillance in the industrial environment].
    Conso F
    Rev Prat; 1987 Apr; 37(23):1321-5. PubMed ID: 3602879
    [No Abstract]   [Full Text] [Related]  

  • 43. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center].
    Hamel JD; Biour M; Cheymol G
    Therapie; 1986; 41(5):327-9. PubMed ID: 3810519
    [No Abstract]   [Full Text] [Related]  

  • 44. [Postmarketing surveillance of adverse reactions of drugs].
    Polli EE; Cortellaro M
    Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
    [No Abstract]   [Full Text] [Related]  

  • 45. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 46. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of an algorithm to evaluate published reports of adverse drug reactions.
    Case B; Oszko MA
    Am J Hosp Pharm; 1991 Jan; 48(1):121-2. PubMed ID: 2000870
    [No Abstract]   [Full Text] [Related]  

  • 48. Program for improving adverse drug reaction reporting.
    Chatas CA; Vinson BE
    Am J Hosp Pharm; 1990 Jan; 47(1):155-7. PubMed ID: 2301425
    [No Abstract]   [Full Text] [Related]  

  • 49. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 50. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 51. Safety in clinical trials.
    Wallander MA
    Scand J Prim Health Care Suppl; 1990; 1():89-91. PubMed ID: 2100372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 54. [Evaluation of medication side-effects from an economic perspective].
    Segura O; Maldonado C
    Biomedica; 2003 Dec; 23(4):401-7. PubMed ID: 14968918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 57. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 58. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 59. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
    Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
    [No Abstract]   [Full Text] [Related]  

  • 60. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.